ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights

Launch of clinical development of avacopan in Hidradenitis Suppurativa (HS), an orphan dermatological disease, remains on track for 2018 –.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *